2020: A blockbuster year for biopharma dealmaking.

Despite cooling M&A activity, deals and financing hit record highs

blockbuster year for biopharma dealmaking

Concerns that societal lockdowns and travel restrictions might curb biopharma mergers, acquisitions and partnering activity have proven unfounded. Indeed, as this review of 2020 pharma industry deal activity highlights, mergers, acquisition and partnering activities across the whole of the global biopharma ecosystem was robust, despite the pandemic.

Deal making, which sees companies collaborating with each other, sharing risks, resources, and potential upside, hit record levels in 2020, with nearly 2,000 transactions valued at almost $200 billion. Download our report to dive deeper into these deals and learn about the most attractive therapeutic area for dealmaking.